Does the media favor COLL or NMRA?

In the previous week, Collegium Pharmaceutical had 5 more articles in the media than Neumora Therapeutics. MarketBeat recorded 9 mentions for Collegium Pharmaceutical and 4 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.21 beat Collegium Pharmaceutical's score of 0.42 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Neumora Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ETON or NMRA?

In the previous week, Eton Pharmaceuticals had 2 more articles in the media than Neumora Therapeutics. MarketBeat recorded 6 mentions for Eton Pharmaceuticals and 4 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.21 beat Eton Pharmaceuticals' score of 1.03 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neumora Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NMRA or MGTX?

In the previous week, Neumora Therapeutics had 2 more articles in the media than MeiraGTx. MarketBeat recorded 4 mentions for Neumora Therapeutics and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.61 beat Neumora Therapeutics' score of 1.21 indicating that MeiraGTx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neumora Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings and valuation, NMRA or SVRA?

Savara is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neumora Therapeutics N/A N/A -$236.93M -$1.33 N/A Savara N/A N/A -$118.84M -$0.56 N/A

Is NMRA or SVRA more profitable?

Savara's return on equity of -87.19% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neumora Therapeutics N/A -181.70% -119.15% Savara N/A -87.19% -66.42%

Does the media favor NMRA or SVRA?

In the previous week, Savara had 1 more articles in the media than Neumora Therapeutics. MarketBeat recorded 5 mentions for Savara and 4 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.21 beat Savara's score of 1.06 indicating that Neumora Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neumora Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Savara 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Neumora Therapeutics (NMRA) Competitors

$1.49 -0.07 (-4.49%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.49 0.00 (0.00%)

As of 07/24/2026 07:34 PM Eastern

Compare

NMRA vs. CALT, COLL, ETON, MGTX, and SVRA

Should you buy Neumora Therapeutics stock or one of its competitors? MarketBeat compares Neumora Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neumora Therapeutics include Calliditas Therapeutics AB (publ) (CALT), Collegium Pharmaceutical (COLL), Eton Pharmaceuticals (ETON), MeiraGTx (MGTX), and Savara (SVRA). These companies are all part of the "pharmaceutical products" industry.

How does Neumora Therapeutics compare to Calliditas Therapeutics AB (publ)?

Neumora Therapeutics (NASDAQ:NMRA) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Neumora Therapeutics presently has a consensus target price of $6.57, indicating a potential upside of 341.04%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Neumora Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Neumora Therapeutics had 4 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 4 mentions for Neumora Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Neumora Therapeutics' average media sentiment score of 1.21 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Neumora Therapeutics	Positive
Calliditas Therapeutics AB (publ)	Neutral

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Neumora Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Neumora Therapeutics has a beta of 2.74, indicating that its share price is 174% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Neumora Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Neumora Therapeutics' return on equity of -181.70% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-181.70%	-119.15%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 26.9% of Neumora Therapeutics shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Neumora Therapeutics beats Calliditas Therapeutics AB (publ) on 13 of the 16 factors compared between the two stocks.

How does Neumora Therapeutics compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

In the previous week, Collegium Pharmaceutical had 5 more articles in the media than Neumora Therapeutics. MarketBeat recorded 9 mentions for Collegium Pharmaceutical and 4 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.21 beat Collegium Pharmaceutical's score of 0.42 indicating that Neumora Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neumora Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Collegium Pharmaceutical has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.74, indicating that its stock price is 174% more volatile than the broader market.

Collegium Pharmaceutical currently has a consensus target price of $57.50, indicating a potential upside of 63.35%. Neumora Therapeutics has a consensus target price of $6.57, indicating a potential upside of 341.04%. Given Neumora Therapeutics' higher probable upside, analysts plainly believe Neumora Therapeutics is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.17
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

47.7% of Neumora Therapeutics shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by company insiders. Comparatively, 26.9% of Neumora Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Collegium Pharmaceutical has higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$796.33M	1.43	$62.87M	$2.04	17.25
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A

Collegium Pharmaceutical has a net margin of 9.41% compared to Neumora Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Neumora Therapeutics	N/A	-181.70%	-119.15%

Summary

Collegium Pharmaceutical beats Neumora Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Neumora Therapeutics compare to Eton Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Eton Pharmaceuticals has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.74, meaning that its stock price is 174% more volatile than the broader market.

27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by company insiders. Comparatively, 26.9% of Neumora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Neumora Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Eton Pharmaceuticals' return on equity of -5.68% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%
Neumora Therapeutics	N/A	-181.70%	-119.15%

Eton Pharmaceuticals presently has a consensus target price of $45.75, suggesting a potential upside of 7.42%. Neumora Therapeutics has a consensus target price of $6.57, suggesting a potential upside of 341.04%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Eton Pharmaceuticals had 2 more articles in the media than Neumora Therapeutics. MarketBeat recorded 6 mentions for Eton Pharmaceuticals and 4 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.21 beat Eton Pharmaceuticals' score of 1.03 indicating that Neumora Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neumora Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eton Pharmaceuticals has higher revenue and earnings than Neumora Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	14.59	-$4.60M	-$0.07	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A

Summary

Neumora Therapeutics beats Eton Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Neumora Therapeutics compare to MeiraGTx?

Neumora Therapeutics (NASDAQ:NMRA) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Neumora Therapeutics has a beta of 2.74, indicating that its stock price is 174% more volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

MeiraGTx has higher revenue and earnings than Neumora Therapeutics. MeiraGTx is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A
MeiraGTx	$79.76M	13.67	-$114.20M	-$1.48	N/A

Neumora Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. MeiraGTx's return on equity of 0.00% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-181.70%	-119.15%
MeiraGTx	-151.12%	N/A	-54.96%

In the previous week, Neumora Therapeutics had 2 more articles in the media than MeiraGTx. MarketBeat recorded 4 mentions for Neumora Therapeutics and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.61 beat Neumora Therapeutics' score of 1.21 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neumora Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 26.9% of Neumora Therapeutics shares are owned by insiders. Comparatively, 7.4% of MeiraGTx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Neumora Therapeutics currently has a consensus target price of $6.57, suggesting a potential upside of 341.04%. MeiraGTx has a consensus target price of $26.00, suggesting a potential upside of 120.90%. Given Neumora Therapeutics' higher probable upside, analysts plainly believe Neumora Therapeutics is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Neumora Therapeutics beats MeiraGTx on 8 of the 15 factors compared between the two stocks.

How does Neumora Therapeutics compare to Savara?

Neumora Therapeutics (NASDAQ:NMRA) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

In the previous week, Savara had 1 more articles in the media than Neumora Therapeutics. MarketBeat recorded 5 mentions for Savara and 4 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.21 beat Savara's score of 1.06 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neumora Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neumora Therapeutics has a beta of 2.74, suggesting that its share price is 174% more volatile than the broader market. Comparatively, Savara has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

Savara's return on equity of -87.19% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-181.70%	-119.15%
Savara	N/A	-87.19%	-66.42%

Neumora Therapeutics currently has a consensus target price of $6.57, suggesting a potential upside of 341.04%. Savara has a consensus target price of $10.14, suggesting a potential upside of 84.08%. Given Neumora Therapeutics' higher probable upside, research analysts plainly believe Neumora Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Savara is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 26.9% of Neumora Therapeutics shares are held by company insiders. Comparatively, 5.3% of Savara shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Savara beats Neumora Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Neumora Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NMRA vs. The Competition

Export

Metric	Neumora Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$276.07M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-1.12	21.48	27.14	23.64
Price / Sales	N/A	170.08	517.06	88.99
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	2.40	7.88	10.28	6.07
Net Income	-$236.93M	$23.86M	$3.60B	$331.99M
7 Day Performance	-7.45%	-3.82%	-1.27%	-0.63%
1 Month Performance	-1.32%	-2.61%	-0.37%	-2.00%
1 Year Performance	-36.60%	32.79%	18.30%	13.62%

Neumora Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NMRA Neumora Therapeutics	3.2946 of 5 stars	$1.49 -4.5%	$6.57 +341.0%	-34.9%	$276.07M	N/A	N/A	108	News Coverage Positive News Analyst Downgrade
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
COLL Collegium Pharmaceutical	3.0672 of 5 stars	$35.54 -1.5%	$57.50 +61.8%	+9.6%	$1.17B	$780.57M	17.42	210	News Coverage Analyst Downgrade
ETON Eton Pharmaceuticals	3.54 of 5 stars	$41.07 -3.0%	$45.75 +11.4%	+177.1%	$1.16B	$79.95M	N/A	20	News Coverage
MGTX MeiraGTx	3.9969 of 5 stars	$12.21 -1.8%	$26.00 +112.9%	+41.6%	$1.15B	$81.39M	N/A	300	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NMRA) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neumora Therapeutics (NMRA) Competitors

NMRA vs. CALT, COLL, ETON, MGTX, and SVRA

How does Neumora Therapeutics compare to Calliditas Therapeutics AB (publ)?

Summary

How does Neumora Therapeutics compare to Collegium Pharmaceutical?

Summary

How does Neumora Therapeutics compare to Eton Pharmaceuticals?

Summary

How does Neumora Therapeutics compare to MeiraGTx?

Summary

How does Neumora Therapeutics compare to Savara?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMRA vs. The Competition

Neumora Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neumora Therapeutics (NMRA) Competitors

NMRA vs. CALT, COLL, ETON, MGTX, and SVRA

How does Neumora Therapeutics compare to Calliditas Therapeutics AB (publ)?

Do analysts rate NMRA or CALT?

Does the media prefer NMRA or CALT?

Which has stronger earnings & valuation, NMRA or CALT?

Which has more volatility & risk, NMRA or CALT?

Is NMRA or CALT more profitable?

Do institutionals & insiders hold more shares of NMRA or CALT?

Summary

How does Neumora Therapeutics compare to Collegium Pharmaceutical?

Does the media favor COLL or NMRA?

Which has more volatility & risk, COLL or NMRA?

Do analysts recommend COLL or NMRA?

Do insiders and institutionals believe in COLL or NMRA?

Which has preferable earnings & valuation, COLL or NMRA?

Is COLL or NMRA more profitable?

Summary

How does Neumora Therapeutics compare to Eton Pharmaceuticals?

Which has more risk & volatility, ETON or NMRA?

Do insiders and institutionals hold more shares of ETON or NMRA?

Is ETON or NMRA more profitable?

Do analysts prefer ETON or NMRA?

Does the media prefer ETON or NMRA?

Which has stronger earnings and valuation, ETON or NMRA?

Summary

How does Neumora Therapeutics compare to MeiraGTx?

Which has more risk & volatility, NMRA or MGTX?

Which has stronger earnings & valuation, NMRA or MGTX?

Is NMRA or MGTX more profitable?

Does the media refer more to NMRA or MGTX?

Do institutionals and insiders have more ownership in NMRA or MGTX?

Do analysts prefer NMRA or MGTX?

Summary

How does Neumora Therapeutics compare to Savara?

Does the media favor NMRA or SVRA?

Which has more volatility and risk, NMRA or SVRA?

Is NMRA or SVRA more profitable?

Do analysts recommend NMRA or SVRA?

Which has better earnings and valuation, NMRA or SVRA?

Do institutionals & insiders have more ownership in NMRA or SVRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMRA vs. The Competition

Neumora Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools